|Day Low/High||2.76 / 2.89|
|52 Wk Low/High||1.99 / 5.05|
We're buying a small position in Inovio Pharmaceuticals and downgrading AcelRx.
We scaled further into one position and added a Bullpen name as the market shrugged off geopolitical uncertainties.
It was a busy week of moves in the portfolio as we head into the latter half of the second quarter.
AcelRx Pharmaceuticals is another interesting, yet speculative, play.
The most recent short interest data was recently released for the 09/30/2016 settlement date, and AcelRx Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 8.72 "days to cover" versus the median component at 5.36. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
AcelRx Pharmaceuticals (ACRX) announced on Thursday that ARX-04, its experimental pain relief drug, had positive results in a phase III clinical trial.
Investors in AcelRx Pharmaceuticals Inc saw new options begin trading this week, for the September 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a weak on high relative volume candidate
Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a strong on high relative volume candidate
There's a valuable, albeit painful, lesson here in Amicus' blow-up. Biotech CEOs should shut their mouths about regulatory plans until they receive definitive word from the FDA.
These stocks look ready to break out and trade higher from current levels.
These under-$10 stocks are within range of triggering breakout trades.
Some biotech stocks way underperformed in this red-hot sector.
Stocks with insider trader activity include LAD, RSE and ACRX
Stocks with insider trader activity include STFC, ACRX and CSC
AcelRx shareholders were burned yet again when the company announced new clinical trials were required for its flagship drug. What's to come for this struggling biotech company?
Shares of AcelRx Pharmaceuticals (ACRX) are extending losses as Jefferies downgraded the company to 'hold' from 'buy.'
AcelRx Pharmaceuticals (ACRX) shares are down over 30% after the company announced a delay to the resubmitting of Zalviso's regulatory application due to increased FDA scrutiny.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
AcelRx Pharmaceuticals was hit with an FDA rejection and is due to resubmit their drug this quarter; should investors stay away or is there an opportunity to be had?
These setups often produce monster moves higher in very short time frames.
AcelRx Pharmaceuticals (ACRX) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CLMS, FCCY, FCS Downgrades: ACRX, MWE, QIHU, RAIL, SBR, TIVO, UCP Initiations: CBMG Read on to get TheStreet Quant Ratings' detailed report:
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on...
Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased or otherwise acquired AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals (ACRX) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.
Shares of AcelRx Pharmaceuticals (ACRX) surged in late morning trading Tuesday after the company reported third-quarter results after the market close Monday that beat analysts' expectations.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACRX, ADT, CMGE, DMRC, FCN, FFBC, GVA, ORBC, PMC, SPOK, TCPC Downgrades: ATVI, BRKR, ICPT, LBIX, LUK, MPAA, PEGA, PHI, RIG Initiations: AAOI, AR, CXP, LDRH, QTS, SFXE, SGM, WNRL, XLRN Read on to get TheStreet Quant Ratings' detailed report:
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.